On the deal, Freshfields advised Zentiva; Ashurst advised APONTIS PHARMA. Zentiva AG announced its decision to make a voluntary public purchase offer for all Apontis shares...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here